NASDAQ:KZR Kezar Life Sciences (KZR) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free KZR Stock Alerts $0.82 +0.03 (+3.79%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$0.79▼$0.8350-Day Range$0.78▼$1.0552-Week Range$0.67▼$3.13Volume709,448 shsAverage Volume700,056 shsMarket Capitalization$59.84 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Kezar Life Sciences alerts: Email Address Kezar Life Sciences MarketRank™ Stock AnalysisAnalyst RatingHold2.33 Rating ScoreUpside/Downside1,238.2% Upside$11.00 Price TargetShort InterestBearish4.90% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.26) to ($1.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.90 out of 5 starsMedical Sector173rd out of 909 stocksPharmaceutical Preparations Industry64th out of 422 stocks 3.2 Analyst's Opinion Consensus RatingKezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageKezar Life Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.90% of the outstanding shares of Kezar Life Sciences have been sold short.Short Interest Ratio / Days to CoverKezar Life Sciences has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Kezar Life Sciences has recently increased by 5.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKezar Life Sciences does not currently pay a dividend.Dividend GrowthKezar Life Sciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKezar Life Sciences has received a 73.01% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Kezar Life Sciences is -0.85. Previous Next 1.9 News and Social Media Coverage News SentimentKezar Life Sciences has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kezar Life Sciences this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for KZR on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows4 people have added Kezar Life Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.90% of the stock of Kezar Life Sciences is held by insiders.Percentage Held by Institutions67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kezar Life Sciences are expected to grow in the coming year, from ($1.26) to ($1.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kezar Life Sciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kezar Life Sciences is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKezar Life Sciences has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Kezar Life Sciences Stock (NASDAQ:KZR)Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Read More KZR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KZR Stock News HeadlinesApril 16, 2024 | americanbankingnews.comKezar Life Sciences, Inc. (NASDAQ:KZR) Short Interest Up 5.6% in MarchApril 8, 2024 | businesswire.comKezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)April 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. March 27, 2024 | investorplace.comFrom Pennies to Fortunes: 3 Stocks Set to Make MillionairesMarch 16, 2024 | investorplace.comDiamonds in the Dust: 3 Penny Stocks Set to Soar 500% by 2026March 14, 2024 | investorplace.comKZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023March 14, 2024 | businesswire.comKezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | finanznachrichten.deEverest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for NefeconApril 23, 2024 | Crypto 101 Media (Ad)[Shocking] Elon Musk’s Plan To End BanksLeaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030. March 3, 2024 | finance.yahoo.comKezar Life Sciences, Inc. (KZR)February 28, 2024 | finance.yahoo.comKezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese MarketFebruary 26, 2024 | businesswire.comEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisFebruary 26, 2024 | prnewswire.comEverest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus NephritisFebruary 25, 2024 | investorplace.com3 Top Penny Stocks for 5,000% Upside in 2024 and BeyondFebruary 22, 2024 | benzinga.comKezar Life Sciences Stock (NASDAQ:KZR) Dividends: History, Yield and DatesFebruary 19, 2024 | thestreet.comKezar Life Sciences Inc.February 10, 2024 | finance.yahoo.com3 Penny Stocks Poised for an Unbelievable 1,000% JumpJanuary 31, 2024 | morningstar.comKezar Life Sciences Inc KZRJanuary 18, 2024 | finance.yahoo.comKZR Jan 2025 17.500 callDecember 26, 2023 | finance.yahoo.comBull Run Bonanza: Top 3 Penny Stocks Primed for Explosive GrowthDecember 5, 2023 | msn.comEverest inches towards clinical studies for renal disease drug in ChinaNovember 27, 2023 | markets.businessinsider.comBuy Rating Affirmed: Kezar Life Sciences’ Promising Trials and Strong FinancialsNovember 27, 2023 | markets.businessinsider.comAnalyst Expectations for Kezar Life Sciences's FutureNovember 21, 2023 | finance.yahoo.comKezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 14, 2023 | benzinga.comKezar Life Sciences Stock (NASDAQ:KZR), Analyst Ratings, Price Targets, PredictionsNovember 13, 2023 | finance.yahoo.comKezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateSee More Headlines Receive KZR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kezar Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/22/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KZR CUSIPN/A CIK1645666 Webwww.kezarlifesciences.com Phone(650) 822-5600FaxN/AEmployees58Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$20.00 Low Stock Price Target$2.00 Potential Upside/Downside+1,238.2%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-101,870,000.00 Net MarginsN/A Pretax Margin-1,455.29% Return on Equity-43.08% Return on Assets-37.59% Debt Debt-to-Equity Ratio0.05 Current Ratio11.66 Quick Ratio11.66 Sales & Book Value Annual Sales$7 million Price / Sales8.55 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book0.32Miscellaneous Outstanding Shares72,800,000Free Float67,050,000Market Cap$59.84 million OptionableNot Optionable Beta0.47 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Christopher J. Kirk Ph.D. (Age 51)Co-Founder, CEO & Director Comp: $677.41kMr. John Franklin Fowler (Age 52)Co-Founder & Director Comp: $919.91kDr. Jack Taunton Ph.D.Co-FounderMr. Marc L. Belsky (Age 69)CFO & Secretary Comp: $491.79kMs. Gitanjali JainVice President of Investor Relations & External AffairsMr. Mark SchillerChief Legal OfficerDr. Neel K. Anand Ph.D.Senior Vice President of Research & Drug DiscoveryDr. Nick Mordwinkin Ph.D. (Age 43)Pharm.D., Chief Business Officer & Head of Strategy Mr. Zung ToSenior Vice President of Clinical DevelopmentMs. Pattie ChiangVP & Corporate ControllerMore ExecutivesKey CompetitorsVaxxinityNASDAQ:VAXXGemini TherapeuticsNASDAQ:GMTXReneo PharmaceuticalsNASDAQ:RPHMHomology MedicinesNASDAQ:FIXXViveon Health AcquisitionNYSE:VHAQView All CompetitorsInstitutional OwnershipAvidity Partners Management LPSold 985,646 shares on 2/14/2024Ownership: 6.914%Panagora Asset Management Inc.Bought 84,087 shares on 2/8/2024Ownership: 0.116%Simplex Trading LLCSold 15,800 shares on 2/2/2024Ownership: 0.000%View All Institutional Transactions KZR Stock Analysis - Frequently Asked Questions Should I buy or sell Kezar Life Sciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kezar Life Sciences in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" KZR shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KZR, but not buy additional shares or sell existing shares. View KZR analyst ratings or view top-rated stocks. What is Kezar Life Sciences' stock price target for 2024? 3 brokerages have issued 12 month target prices for Kezar Life Sciences' stock. Their KZR share price targets range from $2.00 to $20.00. On average, they expect the company's share price to reach $11.00 in the next year. This suggests a possible upside of 1,238.2% from the stock's current price. View analysts price targets for KZR or view top-rated stocks among Wall Street analysts. How have KZR shares performed in 2024? Kezar Life Sciences' stock was trading at $0.9474 on January 1st, 2024. Since then, KZR stock has decreased by 13.2% and is now trading at $0.8220. View the best growth stocks for 2024 here. Are investors shorting Kezar Life Sciences? Kezar Life Sciences saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 3,570,000 shares, an increase of 5.6% from the March 15th total of 3,380,000 shares. Based on an average daily trading volume, of 717,500 shares, the short-interest ratio is presently 5.0 days. View Kezar Life Sciences' Short Interest. When is Kezar Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our KZR earnings forecast. How were Kezar Life Sciences' earnings last quarter? Kezar Life Sciences, Inc. (NASDAQ:KZR) issued its quarterly earnings data on Thursday, March, 14th. The company reported ($0.35) earnings per share for the quarter, beating analysts' consensus estimates of ($0.39) by $0.04. What other stocks do shareholders of Kezar Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kezar Life Sciences investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Pfizer (PFE), VYNE Therapeutics (vyne), Dynavax Technologies (DVAX), Gilead Sciences (GILD), AbbVie (ABBV), Aldeyra Therapeutics (ALDX) and Exelixis (EXEL). When did Kezar Life Sciences IPO? Kezar Life Sciences (KZR) raised $70 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,700,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair served as the underwriters for the IPO. How do I buy shares of Kezar Life Sciences? Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KZR) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
